{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:03:28Z","timestamp":1792706608422,"version":"4.5.0"},"reference-count":186,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ajps.2024.100980","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T05:51:34Z","timestamp":1730094694000},"page":"100980","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Biopharmaceutical and pharmacokinetic attributes to drive nanoformulations of small molecule tyrosine kinase inhibitors"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0025-8068","authenticated-orcid":false,"given":"Soumyadip","family":"Mukherjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4151-717X","authenticated-orcid":false,"given":"Vedant","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kolimi Prashanth","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7404-4917","authenticated-orcid":false,"given":"Pallab","family":"Datta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.ajps.2024.100980_bib0001","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajps.2024.100980_bib0002","article-title":"Complex formulation strategies to overcome the delivery hurdles of lapatinib in metastatic breast cancer","volume":"82","author":"Singh","year":"2023","journal-title":"J Drug Deliv Sci Technol"},{"issue":"10","key":"10.1016\/j.ajps.2024.100980_bib0003","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ajps.2024.100980_bib0004","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ajps.2024.100980_bib0005","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.phrs.2019.03.006","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors","volume":"144","author":"Roskoski","year":"2019","journal-title":"Pharmacol Res"},{"issue":"7869","key":"10.1016\/j.ajps.2024.100980_bib0006","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41586-021-03741-7","article-title":"EGFR activation limits the response of liver cancer to lenvatinib","volume":"595","author":"Jin","year":"2021","journal-title":"Nature"},{"issue":"641","key":"10.1016\/j.ajps.2024.100980_bib0007","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abm6420","article-title":"A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy","volume":"14","author":"Msaouel","year":"2022","journal-title":"Sci Transl Med"},{"issue":"7878","key":"10.1016\/j.ajps.2024.100980_bib0008","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ajps.2024.100980_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00977-0","article-title":"Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020)","volume":"13","author":"Huang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ajps.2024.100980_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108256","article-title":"Recent advances in metabolism and toxicity of tyrosine kinase inhibitors","volume":"237","author":"Zhao","year":"2022","journal-title":"Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.ajps.2024.100980_bib0010","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1365-2125.2004.02117.x","article-title":"In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia","volume":"58","author":"Kretz","year":"2004","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.ajps.2024.100980_bib0011","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ajps.2024.100980_bib0012","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00228-007-0396-z","article-title":"The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP\u2122) predicts in vivo metabolic inhibition","volume":"64","author":"Rakhit","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"issue":"1\u20132","key":"10.1016\/j.ajps.2024.100980_bib0013","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ijpharm.2017.07.010","article-title":"Improving the solubility of nilotinib through novel spray-dried solid dispersions","volume":"529","author":"Herbrink","year":"2017","journal-title":"Int J Pharm"},{"key":"10.1016\/j.ajps.2024.100980_bib0014","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.pharmthera.2015.05.009","article-title":"Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors","volume":"152","author":"Terada","year":"2015","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.ajps.2024.100980_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40364-021-00324-6","article-title":"Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC","volume":"9","author":"Ma","year":"2021","journal-title":"Biomark Res"},{"issue":"5","key":"10.1016\/j.ajps.2024.100980_bib0016","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ctrv.2015.03.005","article-title":"Variability in bioavailability of small molecular tyrosine kinase inhibitors","volume":"41","author":"Herbrink","year":"2015","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.ajps.2024.100980_bib0017","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(22)00793-8","article-title":"Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2\/3 trial","volume":"24","author":"Brown","year":"2023","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ajps.2024.100980_bib0018","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1016\/S2352-3026(17)30066-2","article-title":"De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial","volume":"4","author":"Clark","year":"2017","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.ajps.2024.100980_bib0019","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3892\/ol.2016.4780","article-title":"Therapeutic drug monitoring and tyrosine kinase inhibitors","volume":"12","author":"Herviou","year":"2016","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ajps.2024.100980_bib0020","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ejca.2021.08.033","article-title":"Therapeutic drug monitoring in oncology: international association of therapeutic drug monitoring and clinical toxicology consensus guidelines for imatinib therapy","volume":"157","author":"Clarke","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ajps.2024.100980_bib0021","first-page":"1","article-title":"Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions","author":"Megyesfalvi","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.ajps.2024.100980_bib0022","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3322\/caac.21728","article-title":"Clinical management of metastatic colorectal cancer in the era of precision medicine","volume":"72","author":"Ciardiello","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.ajps.2024.100980_bib0023","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/cncy.22516","article-title":"Precision medicine in aggressive thyroid cancer: moving beyond multitargeted tyrosine kinase inhibitors","volume":"130","author":"Mahmood","year":"2022","journal-title":"Cancer Cytopathol"},{"issue":"12","key":"10.1016\/j.ajps.2024.100980_bib0024","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.3324\/haematol.2019.231753","article-title":"Are we ready to use precision medicine in chronic myeloid leukemia practice?","volume":"104","author":"Hwan Kim","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.ajps.2024.100980_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1348112","article-title":"Emerging therapeutic drug monitoring technologies: considerations and opportunities in precision medicine","volume":"15","author":"Liang","year":"2024","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1016\/j.ajps.2024.100980_bib0026","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.3390\/pharmaceutics14081676","article-title":"Imatinib optimized therapy improves major molecular response rates in patients with chronic myeloid leukemia","volume":"14","author":"Johnson-Ansah","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.ajps.2024.100980_bib0028","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: progress, challenges and opportunities","volume":"17","author":"Shi","year":"2016","journal-title":"Nat Rev Canc"},{"issue":"1","key":"10.1016\/j.ajps.2024.100980_bib0029","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1021\/acsnano.6b08244","article-title":"Mechanisms and barriers in cancer nanomedicine: addressing challenges, looking for solutions","volume":"11","author":"Anchordoquy","year":"2017","journal-title":"ACS Nano"},{"key":"10.1016\/j.ajps.2024.100980_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114482","article-title":"Engineering nanosystems to overcome barriers to cancer diagnosis and treatment","volume":"189","author":"Alhaj-Suliman","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"10.1016\/j.ajps.2024.100980_bib0031","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"10.1016\/j.ajps.2024.100980_bib0032","doi-asserted-by":"crossref","first-page":"18541","DOI":"10.1021\/acsnano.1c08632","article-title":"Targeting cancer chemotherapy resistance by precision medicine-driven nanoparticle-formulated cisplatin","volume":"15","author":"Siemer","year":"2021","journal-title":"ACS Nano"},{"issue":"23","key":"10.1016\/j.ajps.2024.100980_bib0033","doi-asserted-by":"crossref","first-page":"10475","DOI":"10.1021\/acs.jmedchem.9b00511","article-title":"Precision cancer nanotherapy: evolving role of multifunctional nanoparticles for cancer active targeting","volume":"62","author":"Ahmad","year":"2019","journal-title":"J Med Chem"},{"issue":"83","key":"10.1016\/j.ajps.2024.100980_bib0034","doi-asserted-by":"crossref","first-page":"eadd1153","DOI":"10.1126\/sciimmunol.add1153","article-title":"STING-activating nanoparticles normalize the vascular-immune interface to potentiate cancer immunotherapy","volume":"8","author":"Wang-Bishop","year":"2023","journal-title":"Sci Immunol"},{"issue":"648","key":"10.1016\/j.ajps.2024.100980_bib0035","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abh1261","article-title":"Delivery of an ectonucleotidase inhibitor with ROS-responsive nanoparticles overcomes adenosine-mediated cancer immunosuppression","volume":"14","author":"Mao","year":"2022","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.ajps.2024.100980_bib0036","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1039\/D3BM01735D","article-title":"Delivery of gefitinib loaded nanoparticles for effectively inhibiting prostate cancer progression","volume":"12","author":"Xiong","year":"2024","journal-title":"Biomater Sci"},{"issue":"4","key":"10.1016\/j.ajps.2024.100980_bib0037","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.trecan.2023.01.003","article-title":"Antibody\u2013drug conjugates: in search of partners of choice","volume":"9","author":"Fuentes-Antr\u00e1s","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ajps.2024.100980_bib0038","article-title":"Delivery of erlotinib for enhanced cancer treatment: an update review on particulate systems","volume":"55","author":"Truong","year":"2020","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.ajps.2024.100980_bib0039","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejpb.2020.11.007","article-title":"Role of nano-lipid formulation of CARP-1 mimetic, CFM-4.17 to improve systemic exposure and response in osimertinib resistant non-small cell lung cancer","volume":"158","author":"Kommineni","year":"2021","journal-title":"Eur J Pharmaceut Biopharmaceut"},{"key":"10.1016\/j.ajps.2024.100980_bib0040","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jconrel.2023.04.006","article-title":"HDACIs and TKIs combinations and their liposomal delivery for cancer treatment","volume":"358","author":"Schelker","year":"2023","journal-title":"J Controlled Rel"},{"key":"10.1016\/j.ajps.2024.100980_bib0041","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jconrel.2023.03.038","article-title":"Membrane fusion-mediated delivery of small-molecule HER2 tyrosine kinase inhibitor for effective tumor chemosensitization","volume":"357","author":"Hao","year":"2023","journal-title":"J Control Release"},{"issue":"4","key":"10.1016\/j.ajps.2024.100980_bib0042","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3934\/biophy.2015.4.476","article-title":"Receptor tyrosine kinase structure and function in health and disease","volume":"2","author":"Karpov","year":"2015","journal-title":"AIMS Biophys"},{"issue":"1","key":"10.1016\/j.ajps.2024.100980_bib0043","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0782-4","article-title":"Mechanisms of receptor tyrosine kinase activation in cancer","volume":"17","author":"Du","year":"2018","journal-title":"Mol. Cancer"},{"issue":"6127","key":"10.1016\/j.ajps.2024.100980_bib0044","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.ajps.2024.100980_bib0045","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.cellsig.2005.03.026","article-title":"Autocrine, paracrine and juxtacrine signaling by EGFR ligands","volume":"17","author":"Singh","year":"2005","journal-title":"Cell Signal"},{"key":"10.1016\/j.ajps.2024.100980_bib0046","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.3389\/fphar.2021.772510","article-title":"Receptor tyrosine kinases and their signaling pathways as therapeutic targets of curcumin in cancer","volume":"12","author":"Sudhesh Dev","year":"2021","journal-title":"Front Pharmacol"},{"issue":"11","key":"10.1016\/j.ajps.2024.100980_bib0047","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.3390\/ijms19113491","article-title":"Receptor tyrosine kinase-targeted cancer therapy","volume":"19","author":"Yamaoka","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.ajps.2024.100980_bib0048","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/01.JTO.0000263712.61697.69","article-title":"Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC)","volume":"2","author":"Gadgeel","year":"2007","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ajps.2024.100980_bib0049","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1126\/scitranslmed.aad5640","article-title":"MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations","volume":"8","author":"Arena","year":"2016","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.ajps.2024.100980_bib0050","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.lungcan.2008.10.016","article-title":"Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI","volume":"65","author":"Yi","year":"2009","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.ajps.2024.100980_bib0051","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/JTO.0000000000000380","article-title":"Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)\u2013pretreated non\u2013small-cell lung cancer patients with brain metastases or leptomeningeal Disease","volume":"10","author":"Hoffknecht","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ajps.2024.100980_bib0052","doi-asserted-by":"crossref","first-page":"ix274","DOI":"10.1016\/S0923-7534(20)33399-8","article-title":"Tumour vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptors (VEGFR) polymorphisms and clinical outcome in advanced renal cell carcinoma patients receiving first line sunitinib","volume":"23","author":"Bianconi","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ajps.2024.100980_bib0053","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ijbiomac.2022.01.113","article-title":"Targeting the PDGF\/PDGFR signaling pathway for cancer therapy: a review","volume":"202","author":"Zou","year":"2022","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.ajps.2024.100980_bib0055","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jconrel.2016.08.036","article-title":"Inherent formulation issues of kinase inhibitors","volume":"239","author":"Herbrink","year":"2016","journal-title":"J Control Rel"},{"issue":"3","key":"10.1016\/j.ajps.2024.100980_bib0056","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm Res"},{"issue":"3","key":"10.1016\/j.ajps.2024.100980_bib0057","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1742-7843.2009.00498.x","article-title":"Predicting drug disposition via application of a biopharmaceutics drug disposition classification system","volume":"106","author":"Benet","year":"2010","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"10.1016\/j.ajps.2024.100980_bib0058","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1208\/s12248-022-00687-0","article-title":"State of the art and uses for the biopharmaceutics drug disposition classification system (BDDCS): new additions, revisions, and citation references","volume":"24","author":"Bocci","year":"2022","journal-title":"AAPS"},{"issue":"3","key":"10.1016\/j.ajps.2024.100980_bib0059","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/hon.2335","article-title":"Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: a focus on cytochrome P450, transporters, and acid suppression therapy","volume":"35","author":"Gay","year":"2017","journal-title":"Hematol Oncol"},{"issue":"4","key":"10.1016\/j.ajps.2024.100980_bib0187","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1208\/s12248-011-9290-9","article-title":"BDDCS applied to over 900 drugs","volume":"13","author":"Benet","year":"2011","journal-title":"AAPS"},{"issue":"5","key":"10.1016\/j.ajps.2024.100980_bib0060","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ctrv.2015.03.005","article-title":"Variability in bioavailability of small molecular tyrosine kinase inhibitors","volume":"41","author":"Herbrink","year":"2015","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.ajps.2024.100980_bib0061","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10637-013-0055-4","article-title":"Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours","volume":"32","author":"Devriese","year":"2014","journal-title":"Invest New Drugs"},{"issue":"24","key":"10.1016\/j.ajps.2024.100980_bib0062","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1158\/1078-0432.CCR-06-1249","article-title":"Sorafenib for the treatment of advanced renal cell carcinoma","volume":"12","author":"Kane","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajps.2024.100980_bib0063","first-page":"4319","article-title":"Characterization of preclinical in vitro and in vivo pharmacokinetics properties for KBP-7018, a new tyrosine kinase inhibitor candidate for treatment of idiopathic pulmonary fibrosis","volume":"9","author":"Huang","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"8","key":"10.1016\/j.ajps.2024.100980_bib0064","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ctrv.2009.08.004","article-title":"Clinical pharmacokinetics of tyrosine kinase inhibitors","volume":"35","author":"van Erp","year":"2009","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"10.1016\/j.ajps.2024.100980_bib0065","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1021\/mp0700209","article-title":"The rule of five revisited: applying log D in place of log P in drug-likeness filters","volume":"4","author":"Bhal","year":"2007","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.ajps.2024.100980_bib0066","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40262-016-0440-1","article-title":"Clinical pharmacokinetics and pharmacodynamics of afatinib","volume":"56","author":"Wind","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"23","key":"10.1016\/j.ajps.2024.100980_bib0067","doi-asserted-by":"crossref","first-page":"9160","DOI":"10.1021\/acs.macromol.9b01348","article-title":"Synthesis of dual sensitive lipid- b-poly(dimethylaminoethyl methacrylate) copolymers, self-assemblies and modulation of cloud point temperatures through physical blends with lipid- b-poly(2-isopropyl-2-oxazoline)","volume":"52","author":"El Asmar","year":"2019","journal-title":"Macromolecules"},{"key":"10.1016\/j.ajps.2024.100980_bib0068","series-title":"Design and development of new nanocarriers","first-page":"365","article-title":"Amphiphilic block copolymers\u2013based micelles for drug delivery","author":"Imran","year":"2018"},{"issue":"4","key":"10.1016\/j.ajps.2024.100980_bib0069","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2174\/1567201817666200210122340","article-title":"Recent advances in self-assembled nanoparticles for drug delivery","volume":"17","author":"Varma","year":"2020","journal-title":"Curr Drug Deliv"},{"issue":"7","key":"10.1016\/j.ajps.2024.100980_bib0070","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/jlcr.3839","article-title":"Nanoparticulate formulations of radiopharmaceuticals: strategy to improve targeting and biodistribution properties","volume":"63","author":"Datta","year":"2020","journal-title":"J Labelled Comp Radiopharm"},{"issue":"3","key":"10.1016\/j.ajps.2024.100980_bib0071","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s11481-006-9032-4","article-title":"Nanotechnology: a focus on nanoparticles as a drug delivery system","volume":"1","author":"Kingsley","year":"2006","journal-title":"J Neuroimmune Pharmacol"},{"issue":"1\u20132","key":"10.1016\/j.ajps.2024.100980_bib0072","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","article-title":"Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review","volume":"65","author":"Maeda","year":"2000","journal-title":"J Controlled Rel"},{"issue":"2","key":"10.1016\/j.ajps.2024.100980_bib0073","doi-asserted-by":"crossref","first-page":"E128","DOI":"10.1208\/aapsj0902015","article-title":"Targeted pharmaceutical nanocarriers for cancer therapy and imaging","volume":"9","author":"Torchilin","year":"2007","journal-title":"The AAPS"},{"issue":"3","key":"10.1016\/j.ajps.2024.100980_bib0074","first-page":"297","article-title":"Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential","volume":"1","author":"Immordino","year":"2006","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.ajps.2024.100980_bib0075","unstructured":"FDA. Highlights of prescribing information. 2024. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/050718s048lbl.pdf."},{"issue":"14","key":"10.1016\/j.ajps.2024.100980_bib0076","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.3390\/nano12142440","article-title":"Nanosponges for drug delivery and cancer therapy: recent advances","volume":"12","author":"Iravani","year":"2022","journal-title":"Nanomaterials"},{"issue":"20","key":"10.1016\/j.ajps.2024.100980_bib0077","doi-asserted-by":"crossref","first-page":"6162","DOI":"10.1158\/1078-0432.CCR-07-0807","article-title":"Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma","volume":"13","author":"Rajkumar","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajps.2024.100980_bib0078","unstructured":"A study using intravenous Paxceed\u2122 to treat patients with rheumatoid arthritis. 2018. Available from: https:\/\/ctv.veeva.com\/study\/a-study-using-intravenous-paxceed-to-treat-patients-with-rheumatoid-arthritis."},{"issue":"5","key":"10.1016\/j.ajps.2024.100980_bib0079","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3390\/nano10050847","article-title":"Polymeric nanocapsules as nanotechnological alternative for drug delivery system: current status, challenges and opportunities","volume":"10","author":"Deng","year":"2020","journal-title":"Nanomaterials"},{"issue":"33","key":"10.1016\/j.ajps.2024.100980_bib0080","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1039\/c2cc17995d","article-title":"Targeting carbon nanotubes against cancer","volume":"48","author":"Fabbro","year":"2012","journal-title":"Chem Commun"},{"issue":"8","key":"10.1016\/j.ajps.2024.100980_bib0081","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.2217\/nnm.10.95","article-title":"Carbon nanotubes in cancer theragnosis","volume":"5","author":"Thakare","year":"2010","journal-title":"Nanomedicine"},{"issue":"1\u20132","key":"10.1016\/j.ajps.2024.100980_bib0146","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ijpharm.2018.03.024","article-title":"Co-delivery of doxorubicin and imatinib by pH sensitive cleavable PEGylated nanoliposomes with folate-mediated targeting to overcome multidrug resistance","volume":"542","author":"Chen","year":"2018","journal-title":"Int J Pharm"},{"key":"10.1016\/j.ajps.2024.100980_bib0147","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jconrel.2021.08.035","article-title":"Imatinib co-loaded targeted realgar nanocrystal for synergistic therapy of chronic myeloid leukemia","volume":"338","author":"Wang","year":"2021","journal-title":"J Control Release"},{"key":"10.1016\/j.ajps.2024.100980_bib0083","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109493","article-title":"Non-small cell lung cancer-targeted, redox-sensitive lipid-polymer hybrid nanoparticles for the delivery of a second-generation irreversible epidermal growth factor inhibitor\u2014Afatinib: in vitro and in vivo evaluation","volume":"120","author":"Wang","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.ajps.2024.100980_bib0085","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.2147\/OTT.S286813","article-title":"Lipid\u2013polymer hybrid nanoparticle-based combination treatment with cisplatin and EGFR\/HER2 receptor-targeting afatinib to enhance the treatment of nasopharyngeal carcinoma","volume":"14","author":"Fu","year":"2021","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ajps.2024.100980_bib0086","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijpharm.2019.02.001","article-title":"Afatinib-loaded immunoliposomes functionalized with cetuximab: a novel strategy targeting the epidermal growth factor receptor for treatment of non-small-cell lung cancer","volume":"560","author":"Lu","year":"2019","journal-title":"Int J Pharm"},{"issue":"2","key":"10.1016\/j.ajps.2024.100980_bib0088","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.bbrc.2019.10.084","article-title":"Apatinib-loaded nanoparticles inhibit tumor growth and angiogenesis in a model of melanoma","volume":"521","author":"Zhang","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"10.1016\/j.ajps.2024.100980_bib0089","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1166\/jbn.2019.2770","article-title":"Anti-colorectal cancer effect via application of polyethylene glycol modified liposomal apatinib","volume":"15","author":"Hu","year":"2019","journal-title":"J Biomed Nanotechnol"},{"key":"10.1016\/j.ajps.2024.100980_bib0090","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2147\/IJN.S125573","article-title":"Cyclic RGD peptide-modified liposomal drug delivery system for targeted oral apatinib administration: enhanced cellular uptake and improved therapeutic effects","volume":"12","author":"Song","year":"2017","journal-title":"Int J Nanomed"},{"issue":"3","key":"10.1016\/j.ajps.2024.100980_bib0093","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1039\/C4TB01442A","article-title":"Systemic delivery of axitinib with nanohybrid liposomal nanoparticles inhibits hypoxic tumor growth","volume":"3","author":"Choi","year":"2014","journal-title":"J Mater Chem B"},{"key":"10.1016\/j.ajps.2024.100980_bib0094","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.actbio.2016.05.012","article-title":"PEGylated lipid bilayer-supported mesoporous silica nanoparticle composite for synergistic co-delivery of axitinib and celastrol in multi-targeted cancer therapy","volume":"39","author":"Choi","year":"2016","journal-title":"Acta Biomater"},{"issue":"2","key":"10.1016\/j.ajps.2024.100980_bib0097","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1158\/1535-7163.MCT-20-0167","article-title":"Cabozantinib unlocks efficient in vivo targeted delivery of neutrophil-loaded nanoparticles into murine prostate tumors","volume":"20","author":"Chaudagar","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ajps.2024.100980_bib0106","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2021.112093","article-title":"Preparation and evaluation of dabrafenib-loaded, CD47-conjugated human serum albumin-based nanoconstructs for chemoimmunomodulation","volume":"208","author":"Pham","year":"2021","journal-title":"Colloids Surf B Biointerfaces"},{"key":"10.1016\/j.ajps.2024.100980_bib0107","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jconrel.2020.09.034","article-title":"Manipulating immune system using nanoparticles for an effective cancer treatment: combination of targeted therapy and checkpoint blockage miRNA","volume":"329","author":"Nguyen","year":"2021","journal-title":"J Control Release"},{"issue":"6","key":"10.1016\/j.ajps.2024.100980_bib0117","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3390\/jpm11060559","article-title":"Enhanced anticancer activity of nanoformulation of dasatinib against triple-negative breast cancer","volume":"11","author":"Bahman","year":"2021","journal-title":"J Pers Med"},{"issue":"6","key":"10.1016\/j.ajps.2024.100980_bib0119","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.ajps.2021.08.001","article-title":"Carrier-free prodrug nanoparticles based on dasatinib and cisplatin for efficient antitumor in vivo","volume":"16","author":"Yang","year":"2021","journal-title":"Asian J Pharm Sci"},{"key":"10.1016\/j.ajps.2024.100980_bib0125","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.2147\/DDDT.S151422","article-title":"Redox-responsive and pH-sensitive nanoparticles enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo","volume":"11","author":"Tan","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ajps.2024.100980_bib0126","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.2147\/DDDT.S169734","article-title":"HA\/HSA co-modified erlotinib-albumin nanoparticles for lung cancer treatment","volume":"12","author":"Shen","year":"2018","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"10.1016\/j.ajps.2024.100980_bib0127","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/10717544.2019.1576801","article-title":"pH sensitive peptide functionalized nanoparticles for co-delivery of erlotinib and DAPT to restrict the progress of triple negative breast cancer","volume":"26","author":"Wan","year":"2019","journal-title":"Drug Deliv"},{"issue":"6","key":"10.1016\/j.ajps.2024.100980_bib0136","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2174\/1573412915666190314124932","article-title":"Enhanced oral bioavailability of ibrutinib encapsulated poly (lactic-co- glycolic acid) nanoparticles: pharmacokinetic evaluation in rats","volume":"15","author":"Alshetaili","year":"2019","journal-title":"Curr Pharm Anal"},{"issue":"8","key":"10.1016\/j.ajps.2024.100980_bib0137","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12249-019-1524-7","article-title":"Fabrication of ibrutinib nanosuspension by quality by design approach: intended for enhanced oral bioavailability and diminished fast fed variability","volume":"20","author":"Rangaraj","year":"2019","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"10.1016\/j.ajps.2024.100980_bib0154","doi-asserted-by":"crossref","first-page":"387","DOI":"10.5530\/ijper.56.2.58","article-title":"Pazopanib colon targeted liposomal drug delivery for colorectal cancer: high-pressure homogenization process optimization and in-vivo evaluation","volume":"56","author":"Lahoti","year":"2022","journal-title":"Indian J Pharmaceut Educ Res"},{"key":"10.1016\/j.ajps.2024.100980_bib0158","doi-asserted-by":"crossref","first-page":"8445","DOI":"10.2147\/IJN.S223920","article-title":"Design and characterisation of novel sorafenib-loaded carbon nanotubes with distinct tumour-suppressive activity in hepatocellular carcinoma","volume":"14","author":"Elsayed","year":"2019","journal-title":"Int J Nanomed"},{"issue":"1","key":"10.1016\/j.ajps.2024.100980_bib0159","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1080\/10717544.2018.1507061","article-title":"Development and characterization of sorafenib-loaded lipid nanocapsules for the treatment of glioblastoma","volume":"25","author":"Clavreul","year":"2018","journal-title":"Drug Deliv"},{"issue":"2","key":"10.1016\/j.ajps.2024.100980_bib0160","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.nano.2017.12.003","article-title":"PEGylated hyaluronic acid-coated liposome for enhanced in vivo efficacy of sorafenib via active tumor cell targeting and prolonged systemic exposure","volume":"14","author":"Mo","year":"2018","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ajps.2024.100980_bib0161","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.2147\/IJN.S237335","article-title":"Sorafenib-loaded nanoparticles based on biodegradable dendritic polymers for enhanced therapy of hepatocellular carcinoma","volume":"15","author":"Li","year":"2020","journal-title":"Int J Nanomed"},{"issue":"5","key":"10.1016\/j.ajps.2024.100980_bib0162","first-page":"6163","article-title":"Preparation, pharmacokinetics, tissue distribution and antitumor effect of sorafenib-incorporating nanoparticles in vivo","volume":"14","author":"Sheng","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ajps.2024.100980_bib0163","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ijpharm.2019.05.064","article-title":"Development of sorafenib loaded nanoparticles to improve oral bioavailability using a quality by design approach","volume":"566","author":"Park","year":"2019","journal-title":"Int J Pharm"},{"key":"10.1016\/j.ajps.2024.100980_bib0165","article-title":"Development of lapatinib nanosponges for enhancing bioavailability","volume":"65","author":"Prabhu","year":"2021","journal-title":"J Drug Deliv Sci Technol"},{"issue":"9","key":"10.1016\/j.ajps.2024.100980_bib0168","first-page":"023","article-title":"Lapatinib-loaded nanocolloidal polymeric micelles for the efficient treatment of breast cancer","volume":"10","author":"Bonde","year":"2020","journal-title":"J Appl Pharm Sci"},{"issue":"3","key":"10.1016\/j.ajps.2024.100980_bib0166","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/03639045.2016.1254238","article-title":"In vitro and in vivo evaluation of paclitaxel\u2013lapatinib-loaded F127 pluronic micelles","volume":"43","author":"Dehghankelishadi","year":"2017","journal-title":"Drug Dev Ind Pharm"},{"issue":"2","key":"10.1016\/j.ajps.2024.100980_bib0170","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.nano.2017.10.010","article-title":"CD44 targeting hyaluronic acid coated lapatinib nanocrystals foster the efficacy against triple-negative breast cancer","volume":"14","author":"Agrawal","year":"2018","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ajps.2024.100980_bib0167","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2021.112012","article-title":"Development of a stable and high loaded liposomal formulation of lapatinib with enhanced therapeutic effects for breast cancer in combination with Caelyx\u00ae: in vitro and in vivo evaluations","volume":"207","author":"Shokooh Saremi","year":"2021","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"12","key":"10.1016\/j.ajps.2024.100980_bib0169","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.3390\/jcm8122214","article-title":"Liposomal lapatinib in combination with low-dose photodynamic therapy for the treatment of glioma","volume":"8","author":"Fisher","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.ajps.2024.100980_bib0180","article-title":"Development of novel S PC-3 gefitinib lipid nanoparticles for effective drug delivery in breast cancer. Tissue distribution studies and cell cytotoxicity analysis","volume":"61","author":"Nayek","year":"2021","journal-title":"J Drug Deliv Sci Technol"},{"issue":"1","key":"10.1016\/j.ajps.2024.100980_bib0181","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1080\/10717544.2017.1384862","article-title":"In vitro and in vivo antitumor effect of gefitinib nanoparticles on human lung cancer","volume":"24","author":"Ni","year":"2017","journal-title":"Drug Deliv"},{"key":"10.1016\/j.ajps.2024.100980_bib0182","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2019.114734","article-title":"Gefitinib and curcumin-loaded nanoparticles enhance cell apoptosis in human oral cancer SAS cells in vitro and inhibit SAS cell xenografted tumor in vivo","volume":"382","author":"Lai","year":"2019","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.ajps.2024.100980_bib0149","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2021.111644","article-title":"Self-assembled phospholipid-based mixed micelles for improving the solubility, bioavailability and anticancer activity of lenvatinib","volume":"201","author":"Zhang","year":"2021","journal-title":"Colloids Surf B Biointerfaces"},{"key":"10.1016\/j.ajps.2024.100980_bib0151","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.actbio.2021.05.018","article-title":"Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer","volume":"129","author":"Chen","year":"2021","journal-title":"Acta Biomater"},{"issue":"1","key":"10.1016\/j.ajps.2024.100980_bib0101","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1080\/10717544.2021.1979129","article-title":"Co-delivery of sorafenib and crizotinib encapsulated with polymeric nanoparticles for the treatment of in vivo lung cancer animal model","volume":"28","author":"Zhong","year":"2021","journal-title":"Drug Deliv"},{"issue":"1","key":"10.1016\/j.ajps.2024.100980_bib0102","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s12032-022-01893-8","article-title":"Crizotinib loaded polydopamine-polylactide-TPGS nanoparticles in chemotherapy for non-small cell lung cancer","volume":"40","author":"Wang","year":"2022","journal-title":"Med Oncol"},{"issue":"8","key":"10.1016\/j.ajps.2024.100980_bib0103","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1080\/1061186X.2017.1419357","article-title":"Micellar formulations of crizotinib and dasatinib in the management of glioblastoma multiforme","volume":"26","author":"Greish","year":"2017","journal-title":"J Drug Target"},{"issue":"3","key":"10.1016\/j.ajps.2024.100980_bib0082","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40262-016-0440-1","article-title":"Clinical pharmacokinetics and pharmacodynamics of afatinib","volume":"56","author":"Wind","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"10.1016\/j.ajps.2024.100980_bib0084","article-title":"Next-generation cancer-specific hybrid theranostic nanomaterials: MAGE-A3 NIR persistent luminescence nanoparticles conjugated to afatinib for in situ suppression of lung adenocarcinoma growth and metastasis","volume":"7","author":"Chan","year":"2020","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"10.1016\/j.ajps.2024.100980_bib0087","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40262-016-0427-y","article-title":"Population pharmacokinetic and covariate analysis of apatinib, an oral tyrosine kinase inhibitor, in healthy volunteers and patients with solid tumors","volume":"56","author":"Yu","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.ajps.2024.100980_bib0091","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10637-020-01023-z","article-title":"Absorption of the orally active multikinase inhibitor axitinib as a therapeutic index to guide dose titration in metastatic renal cell carcinoma","volume":"39","author":"Fukudo","year":"2021","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ajps.2024.100980_bib0092","unstructured":"Axitinib (AG 013736) as second line therapy for metastatic renal cell cancer. 2022. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00920816."},{"issue":"5","key":"10.1016\/j.ajps.2024.100980_bib0095","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40262-016-0461-9","article-title":"Clinical pharmacokinetics and pharmacodynamics of cabozantinib","volume":"56","author":"Lacy","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.ajps.2024.100980_bib0096","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100312","article-title":"Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics\/pharmacodynamics study","volume":"6","author":"Cerbone","year":"2021","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.ajps.2024.100980_bib0098","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40262-018-0689-7","article-title":"Clinical pharmacokinetics of anaplastic lymphoma kinase inhibitors in non-small-cell lung cancer","volume":"58","author":"Hirota","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"10.1016\/j.ajps.2024.100980_bib0099","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1517\/14656566.2012.688029","article-title":"Crizotinib in the treatment of non-small-cell lung cancer","volume":"13","author":"Forde","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ajps.2024.100980_bib0100","unstructured":"A Study comparing alectinib with crizotinib in treatment-naive anaplastic lymphoma kinase-positive advanced non-small cell lung cancer participants. 2014. Available from: https:\/\/clinicaltrials.ucsf.edu\/trial\/NCT02075840."},{"issue":"4","key":"10.1016\/j.ajps.2024.100980_bib0104","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s40262-018-0703-0","article-title":"Clinical pharmacokinetics and pharmacodynamics of dabrafenib","volume":"58","author":"Puszkiel","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ajps.2024.100980_bib0105","unstructured":"Center for drug evaluation and research. Application number: 202806Orig1s000. 2013. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/202806Orig1s000Approv.pdf."},{"issue":"7","key":"10.1016\/j.ajps.2024.100980_bib0108","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40262-020-00872-4","article-title":"Clinical pharmacokinetics and pharmacodynamics of dasatinib","volume":"59","author":"Lev\u00eaque","year":"2020","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.ajps.2024.100980_bib0109","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/cpt.787","article-title":"Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology","volume":"102","author":"Verheijen","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.ajps.2024.100980_bib0110","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1177\/0091270008320604","article-title":"Importance of characterizing determinants of variability in exposure: application to dasatinib in subjects with chronic myeloid leukemia","volume":"48","author":"Dai","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ajps.2024.100980_bib0111","unstructured":"Chandani R., He J., Trabelsi F. Atypical pharmacokinetic profiles observed with dasatinib reference listed drug product in bioequivalence studies. 2017. Available from: https:\/\/www.biopharmaservices.com\/wp-content\/uploads\/2021\/03\/Poster-1-Dasatinib-final-AAPS-2017.pdf."},{"issue":"2","key":"10.1016\/j.ajps.2024.100980_bib0112","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00228-015-1968-y","article-title":"Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia","volume":"72","author":"Ishida","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ajps.2024.100980_bib0113","first-page":"85","article-title":"Differential effects of dosing regimen on the safety and efficacy of dasatinib:retrospective exposure-response analysis of a phase III study","volume":"5","author":"Wang","year":"2013","journal-title":"Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.ajps.2024.100980_bib0114","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00280-007-0478-8","article-title":"Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL","volume":"61","author":"Kamath","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"issue":"23","key":"10.1016\/j.ajps.2024.100980_bib0115","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.1158\/1078-0432.CCR-06-1112","article-title":"Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure","volume":"12","author":"Luo","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajps.2024.100980_bib0116","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejps.2015.05.013","article-title":"In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib","volume":"76","author":"Tsume","year":"2015","journal-title":"Eur J Pharmaceut Sci"},{"key":"10.1016\/j.ajps.2024.100980_bib0118","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.797881","article-title":"Therapeutic drug monitoring and individualized medicine of dasatinib: focus on clinical pharmacokinetics and pharmacodynamics","volume":"12","author":"He","year":"2021","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.ajps.2024.100980_bib0120","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1592\/phco.29.7.858","article-title":"Pharmacokinetics of erlotinib for the treatment of high-grade glioma in a pediatric patient with cystic fibrosis: case report and review of the literature","volume":"29","author":"Christiansen","year":"2009","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.ajps.2024.100980_bib0121","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1177\/0091270005284193","article-title":"Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects","volume":"46","author":"Frohna","year":"2006","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.ajps.2024.100980_bib0122","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2165\/11587020-000000000-00000","article-title":"Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines","volume":"50","author":"Scheffler","year":"2011","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.ajps.2024.100980_bib0123","doi-asserted-by":"crossref","first-page":"332","DOI":"10.4103\/0366-6999.174484","article-title":"Evaluation of three small molecular drugs for targeted therapy to treat nonsmall cell lung cancer","volume":"129","author":"Ni","year":"2016","journal-title":"Chin Med J (Engl)"},{"issue":"2","key":"10.1016\/j.ajps.2024.100980_bib0124","first-page":"189","article-title":"Drug-drug interactions, safety, and pharmacokinetics of EGFR tyrosine kinase inhibitors for the treatment of non\u2013small cell lung cancer","volume":"9","author":"Kucharczuk","year":"2018","journal-title":"J Adv Pract Oncol"},{"issue":"2","key":"10.1016\/j.ajps.2024.100980_bib0128","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bcp.12787","article-title":"Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults","volume":"81","author":"De Vries","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.ajps.2024.100980_bib0129","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/jphp.12550","article-title":"Bioavailability enhancement and pharmacokinetic profile of an anticancer drug ibrutinib by self-nanoemulsifying drug delivery system","volume":"68","author":"Shakeel","year":"2016","journal-title":"J Pharm Pharmacol"},{"issue":"S1","key":"10.1016\/j.ajps.2024.100980_bib0130","first-page":"1","article-title":"Modulation of CYP3A activity to increase the oral bioavailability of ibrutinib","volume":"34","author":"Eisenmann","year":"2020","journal-title":"FASEB J"},{"key":"10.1016\/j.ajps.2024.100980_bib0131","doi-asserted-by":"crossref","DOI":"10.1016\/j.jct.2023.107050","article-title":"Solubility of ibrutinib in supercritical carbon dioxide (Sc-CO2): data correlation and thermodynamic analysis","volume":"182","author":"Sodeifian","year":"2023","journal-title":"J Chem Thermodyn"},{"issue":"16","key":"10.1016\/j.ajps.2024.100980_bib0132","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ajps.2024.100980_bib0133","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1002\/cncr.30596","article-title":"Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ajps.2024.100980_bib0134","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/ajh.25214","article-title":"Acute myeloid leukemia: 2019 update on risk-stratification and management","volume":"93","author":"Estey","year":"2018","journal-title":"Am J Hematol"},{"issue":"15_suppl","key":"10.1016\/j.ajps.2024.100980_bib0135","doi-asserted-by":"crossref","first-page":"7056","DOI":"10.1200\/jco.2013.31.15_suppl.7056","article-title":"Pharmacokinetics (PK) of ibrutinib in patients with chronic lymphocytic leukemia (CLL)","volume":"31","author":"Sukbuntherng","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajps.2024.100980_bib0138","doi-asserted-by":"crossref","DOI":"10.1016\/j.jct.2019.106031","article-title":"Solubility profile of imatinib in pure and mixed solvents and calculation of thermodynamic properties","volume":"144","author":"Yang","year":"2020","journal-title":"J Chem Thermodyn"},{"key":"10.1016\/j.ajps.2024.100980_bib0139","unstructured":"Buckingham R. Martindale : the complete drug reference. Pharmaceutical Press;2020."},{"key":"10.1016\/j.ajps.2024.100980_bib0140","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/B978-0-12-800173-8.00006-4","article-title":"Imatinib mesylate","volume":"39","author":"Al-Hadiya","year":"2014","journal-title":"Profiles Drug Subst Excip Relat Methodol"},{"issue":"1","key":"10.1016\/j.ajps.2024.100980_bib0141","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/cncr.11863","article-title":"The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase","volume":"100","author":"Sneed","year":"2004","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ajps.2024.100980_bib0142","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4103\/0971-5851.123752","article-title":"Therapeutic drug monitoring for imatinib: current status and Indian experience","volume":"34","author":"Arora","year":"2013","journal-title":"Indian J Med Paediatr Oncol"},{"key":"10.1016\/j.ajps.2024.100980_bib0143","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejca.2020.05.025","article-title":"Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours \u2013 results from daily clinical practice","volume":"136","author":"IJzerman","year":"2020","journal-title":"Eur J Cancer"},{"issue":"22","key":"10.1016\/j.ajps.2024.100980_bib0144","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1002\/cncr.34478","article-title":"Imatinib dose optimization based on therapeutic drug monitoring in Chinese patients with chronic-phase chronic myeloid leukemia","volume":"128","author":"Cheng","year":"2022","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ajps.2024.100980_bib0145","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4103\/0971-5851.123752","article-title":"Therapeutic drug monitoring for imatinib: current status and indian experience","volume":"34","author":"Arora","year":"2013","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"6","key":"10.1016\/j.ajps.2024.100980_bib0148","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/bcp.13223","article-title":"Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer","volume":"83","author":"Brown","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.ajps.2024.100980_bib0150","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/bcp.13223","article-title":"Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer","volume":"83","author":"Brown","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.ajps.2024.100980_bib0152","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s40262-017-0510-z","article-title":"Clinical pharmacokinetics and pharmacodynamics of pazopanib: towards optimized dosing","volume":"56","author":"Verheijen","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.ajps.2024.100980_bib0153","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3109\/00498254.2012.734642","article-title":"Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer","volume":"43","author":"Deng","year":"2013","journal-title":"Xenobiotica"},{"issue":"2","key":"10.1016\/j.ajps.2024.100980_bib0155","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1021\/acs.molpharmaceut.5b00837","article-title":"Improving oral bioavailability of sorafenib by optimizing the \u201cspring\u201d and \u201cparachute\u201d Based on Molecular Interaction Mechanisms","volume":"13","author":"Liu","year":"2016","journal-title":"Mol Pharm"},{"issue":"23","key":"10.1016\/j.ajps.2024.100980_bib0156","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.21037\/atm-21-3768","article-title":"Strategies to improve sorafenib efficacy during image-guided treatment of hepatocellular carcinoma","volume":"9","author":"Eresen","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ajps.2024.100980_bib0157","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113393","article-title":"Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancer","volume":"153","author":"Guchelaar","year":"2022","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"10.1016\/j.ajps.2024.100980_bib0164","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1007\/s13346-022-01142-5","article-title":"Enhanced oral bioavailability and antitumor therapeutic efficacy of sorafenib administered in core-shell protein nanoparticle","volume":"12","author":"Gopakumar","year":"2022","journal-title":"Drug Deliv Transl Res"},{"issue":"4","key":"10.1016\/j.ajps.2024.100980_bib0171","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00280-013-2251-5","article-title":"Effects of pemetrexed, gefitinib, and their combination on human colorectal cancer cells","volume":"72","author":"Zhang","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"20","key":"10.1016\/j.ajps.2024.100980_bib0172","doi-asserted-by":"crossref","first-page":"7480","DOI":"10.1158\/1078-0432.CCR-05-0328","article-title":"Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy","volume":"11","author":"Van Schaeybroeck","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ajps.2024.100980_bib0173","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1124\/jpet.105.084145","article-title":"Role of tyrosine kinase inhibitors in cancer therapy","volume":"315","author":"Arora","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"issue":"9","key":"10.1016\/j.ajps.2024.100980_bib0174","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11090469","article-title":"Development and evaluation of multifunctional poly(lactic-co-glycolic acid) nanoparticles embedded in carboxymethyl \u03b2-glucan porous microcapsules as a novel drug delivery system for gefitinib","volume":"11","author":"Li","year":"2019","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.ajps.2024.100980_bib0175","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1073\/pnas.0409773102","article-title":"ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines","volume":"102","author":"Engelman","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ajps.2024.100980_bib0176","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2019.112211","article-title":"Solubility determination and three dimensional Hansen solubility parameters of gefitinib in different organic solvents: experimental and computational approaches","volume":"299","author":"Alanazi","year":"2020","journal-title":"J Mol Liq"},{"issue":"1","key":"10.1016\/j.ajps.2024.100980_bib0177","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11095-015-1771-6","article-title":"Novel gefitinib formulation with improved oral bioavailability in treatment of A431 skin carcinoma","volume":"33","author":"Godugu","year":"2016","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.ajps.2024.100980_bib0178","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1200\/JCO.2005.04.057","article-title":"Practical management of patients with non-small-cell lung cancer treated with gefitinib","volume":"23","author":"Shah","year":"2005","journal-title":"J Clin Oncol"},{"issue":"9352","key":"10.1016\/j.ajps.2024.100980_bib0179","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0140-6736(03)12190-3","article-title":"Severe acute interstitial pneumonia and gefitinib","volume":"361","author":"Inoue","year":"2003","journal-title":"The Lancet"},{"issue":"3","key":"10.1016\/j.ajps.2024.100980_bib0183","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.3390\/ijms24032312","article-title":"Cabozantinib, vandetanib, pralsetinib and selpercatinib as treatment for progressed medullary thyroid cancer with a main focus on hypertension as adverse effect","volume":"24","author":"H\u00f8jer Wang","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1\u20132","key":"10.1016\/j.ajps.2024.100980_bib0184","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1080\/03602532.2022.2149775","article-title":"Metabolic activation of tyrosine kinase inhibitors: recent advance and further clinical practice","volume":"55","author":"Yan","year":"2023","journal-title":"Drug Metab Rev"},{"issue":"1","key":"10.1016\/j.ajps.2024.100980_bib0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-022-01320-5","article-title":"Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies","volume":"15","author":"Tian","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.ajps.2024.100980_bib0186","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3390\/gels8010045","article-title":"Drug delivery based on stimuli-responsive injectable hydrogels for breast cancer therapy: a Review","volume":"8","author":"Xin","year":"2022","journal-title":"Gels"}],"container-title":["Asian Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1818087624000977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1818087624000977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T15:18:27Z","timestamp":1736435907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1818087624000977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":186,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1818087624000977"],"URL":"https:\/\/doi.org\/10.1016\/j.ajps.2024.100980","relation":{},"ISSN":["1818-0876"],"issn-type":[{"value":"1818-0876","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biopharmaceutical and pharmacokinetic attributes to drive nanoformulations of small molecule tyrosine kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajps.2024.100980","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Shenyang Pharmaceutical University. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100980"}}